Last Price$81.91NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/23/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$81.81 (1)
Ask (Size)$89.99 (1)
Day Low / HighN/A - N/A
Volume1.2 M

View Biotechnology IndustryPeer Comparison as of 08/23/2019


Incyte Corp ( NASDAQ )

Price: $81.91
Change: -3.65 (4.27%)
Volume: 1.2 M
4:00PM ET 8/23/2019

Exact Sciences Corp ( NASDAQ )

Price: $116.96
Change: -0.91 (0.77%)
Volume: 1.2 M
4:00PM ET 8/23/2019

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $75.76
Change: -1.64 (2.12%)
Volume: 1.2 M
4:00PM ET 8/23/2019

Agilent Technologies Inc ( NYSE )

Price: $69.55
Change: -2.19 (3.05%)
Volume: 3.0 M
6:30PM ET 8/23/2019

Seattle Genetics Inc ( NASDAQ )

Price: $76.29
Change: -2.07 (2.64%)
Volume: 495.6 K
4:00PM ET 8/23/2019

Read more news Recent News

Incyte, Eli Lily Say Baricitinib for Atopic Dermatitis Meets Targets in Late-Stage Trial
4:00PM ET 8/23/2019 MT Newswires

Incyte (INCY) and Eli Lilly (LLY) said on Friday a late-stage trial of baricitinib to treat moderate to severe atopic dermatitis (AD) in adults has met its...

S&P 500 Movers: Nektar Therapeutics Tumbles 11%, Leads Losers; Amgen Climbs 5.4%
12:06PM ET 8/12/2019 MT Newswires

S&P 500 Top % Movers as of 12:06 pm ET Gainers AMGN, +5.4% SYY, +3.7% NWSA, +3% NWS, +2.9% INCY, +2.1% Losers NKTR, -11% DXC, -5.5% CPRI, -5.4% ...

Analysts Increase Expectations for Incyte's Q3 and 2020 Earnings
1:11AM ET 8/06/2019 MT Newswires

The Q3 and 2020 forecasted earnings estimates for Incyte Corp's (NASDAQ:INCY, Recent Price: 80.92) for the quarter ending September 30, 2019 and year...

Insider Trends: 90-Day Insider Buying Trend at Incyte Slowed with Sale of Shares
4:41PM ET 8/05/2019 MT Newswires

Jean Jacques Bienaime, Director, sold 1,724 shares in Incyte (INCY) on Aug 01, 2019, for $146,654. Bienaime, subsequent to the transactions designated in...

Company Profile

Business DescriptionIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. View company web site for more details
Address1801 Augustine Cut-Off
Wilmington, Delaware 19803
Number of Employees1,367
Recent SEC Filing08/19/20194
Chairman, President & Chief Executive OfficerHervé Hoppenot
Chief Financial Officer & Executive Vice PresidentChristiana Stamoulis
Chief Medical Officer & Executive Vice PresidentSteven H. Stein
Chief Scientific Officer & Executive VPDashyant Dhanak

Company Highlights

Price Open$85.56
Previous Close$85.56
52 Week Range$57.00 - 89.30
Market Capitalization$17.6 B
Shares Outstanding215.1 M
SectorHealth Technology
Next Earnings Announcement10/29/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings58.09
Earnings per Share$1.54
Beta vs. S&P 500N/A
Revenue$1.9 B
Net Profit Margin15.25%
Return on Equity15.18%

Analyst Ratings as of 07/23/2019

Consensus RecommendationConsensus Icon
Powered by Factset